CAR-T Gene Therapy Approved this Week

Max Former Hodgkins Stage 3

http://www.dana-farber.org/newsroom/news-releases/2017/fda-approves-car-t-cell-therapy-for-non-hodgkin-lymphoma/

Max Former Hodgkins Stage 3

This Paste worked....

Announcement this week approving CAR-T for new uses against some types of relapsed Non-Hodgkin's.....   Coudn't get the paste function to work in block above.

Reportedly for aggressive B-cell strains, not indolent, and only for patients who failed some earlier form of first-line therapy.  What commonly happens is these new discoveries are later found effective against other types of disease also.

max

http://www.dana-farber.org/newsroom/news-releases/2017/fda-approves-car-t-cell-therapy-for-non-hodgkin-lymphoma/

 

.

Evarista

Yescarta also targets CD19

In case anyone is wondering:  like the previously approved CAR-T therapy for ALL, Yescarta also targets the CD19 molecule on the surface of most B cells and B lymphomas (most, but not all).  Anxiously awaiting the CAR-T therapy for CD19 negative DLBCL...I believe a CD22 version is in the works somewhere.

illead

Thank you Max

I was going to send this earlier, but have been overwhelmed with other "stuff" .  This is the clinical trial that Dr Wang at MD Anderson is directing for MCL and wants to put Bill on.   At the time he was relapsed but is now in remission again.  We go every 2 months for pet scans etc. and will go again in Dec.  One of the doctors on his staff says the longer he stays in remission the better, more time for perfecting it.  So Car-T has not been approved yet for Mantle Cell but is for DLBCL and 2 others which are in the following article from the Lymphoma Research Foundation (LRF).  This is a real breakthrough in cancer research and could have promise for other types of cancer.  The negative side is that it is very expensive and I don't think anyone knows how insurance or medicare is going to deal with the coverage. 

Take care,

Becky

 

 

On October 18, 2017, the U.S. Food and Drug Administration (FDA) approved the use of CAR T-Cell therapy, axicabtagene ciloleucel (Yescarta TM, Kite, a Gilead Company),to treat patients with large B-cell lymphoma who have relapsed or have not responded to at least two previous lines of therapy. Only the second gene therapy approved by the FDA, this approval of the chimeric antigen receptor (CAR) T cell therapy, represents the first indication of gene therapy for lymphoma patients.

 

 

 

 

 

CAR-T cell therapy is a type of immunotherapy that uses a patient’s own cells to improve their immune system’s anti-cancer response. CAR-T cell therapies provide engineered molecules called chimeric antigen receptors (CARs) that recognize and destroy antigens present on the surface of lymphoma cells, and are manufactured individually for each patient. The FDA has approved this CAR-T cell therapy for use in diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma (transformed follicular lymphoma, or TFL) patients with relapsed / refractory disease after two previous treatments.

 

Read more about this approval on FocusOnDLBCL.org/FDAUpdates or on the FDA's website. You can also read the Lymphoma Research Foundation's (LRF) official statement.

 

For additional information on this approval contact the LRF Helpline at (800) 500-9976 or helpline@lymphoma.org. LRF's trained staff is available to provide you with information on large B-cell lymphoma, CAR-T cell therapy, and answer your specific questions about this approval. 

 

LRF is committed to providing those impacted by lymphoma with the resources they need to better understand their disease and make the most informed decisions about their treatment and long term care. The Foundation has developed a series of educational resources specifically for immunotherapy, including:

In-Person Education Conference:

The 2017 North American Educational Forum on Lymphoma, taking place this weekend (October 20-22) in Brooklyn, NY, will feature a dedicated lunch and learn session on Lymphoma Immunotherapies. This session will provide information on the various immunotherapies that are used for the treatment of lymphoma, including CAR-T therapy. Register today to learn more about this new treatment option for certain lymphoma patients.

Register Today

Free Publications:

Immunotherapy and Lymphoma Fact Sheet

 

Teleconferences and Videos:

Immunotherpay and Lymphoma Treatment
Bruce D. Cheson, MD, FACP, FAAAS, Georgetown University Hospital, Lombardi Comprehensive Cancer Center

 

Stephen J. Schuster, MD, Hospital of the University of Pennsylvania

 

Advances in Immunotherapy in the Treatment of Lymphoma
Bruce D. Cheson, MD, FACP, FAAAS, Georgetown University Hospital, Lombardi Comprehensive Cancer Center

 

Mobile App:

Focus On Lymphoma Mobile App

The Lymphoma Research Foundation is also developing a suite of educational materials specifically for CAR-T cell therapy. Please check the Foundation’s website (www.lymphoma.org) for updates on these new materials.

Max Former Hodgkins Stage 3

Wow

You gave us the Encyclopedia accout, Becky !  Thank you.

"Stuff": it is what American's do.   I used to love Chuck Barris and his origincal Gong Show.  They were going to a commercial break one day and he looked at the camera and said, "We'll be back in a minute with more....eh....stuff !"  He knew it wasn't quality stuff, or good stuff, just "stuff."   

Would write more, but got stuff to attend to.  Bless you two, delighted to hear Bill is such a trooper !

max

illead

Thanks Max

You just gave Bill and me the chuckle of the day.  Bill said "It's fun to talk to people of our generation who have walked the walk and talked the talk". Oh yes the Gong Show 

Becky

PS: I'm getting my stuff done

 

lindary

Stuff

Yep. It's a word I like to use.